A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas

NCT ID: NCT01140737

Last Updated: 2021-03-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 145 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-08-31
• Study Completion Date: 2019-01-08

Brief Summary

The study objective is to evaluate the therapeutic activity, safety and tolerability of axitinib in patients with advanced/metastatic soft tissue sarcoma who are unsuitable for or have relapsed after standard chemotherapy. The therapeutic activity will be separately assessed in angiosarcoma, synovial sarcoma, leiomyosarcomas and other sarcomas.

Detailed Description

Soft tissue sarcomas are a heterogeneous group of rare malignancies that account for 0.72% of new malignancies and 0.65% of malignant deaths. Advanced sarcomas carry a poor prognosis. Angiogenesis is a hallmark of tumour growth, and there is increasing evidence that antiangiogenic drugs, including axitinib, can lead to tumour regression and improve patient survival in a variety of tumours.

Patients with angiosarcoma, synovial sarcoma, leiomyosarcoma and other sarcomas will be separately evaluated.

Patients will take axitinib 5mg tablets by mouth twice daily. This will be continued for 2 years or until disease progression, or development of limiting toxicity. In the event of severe toxicity, axitinib will be stopped until the toxicity has improved. Treatment may be interrupted for a maximum of 2 weeks. Following this, axitinib can be restarted at a lower dose of 3 mg twice daily. If the toxicity has not improved sufficiently, axitinib will be permanently stopped.

Patients will be monitored once weekly for the first month, then at 4 week intervals. Toxicity will be closely monitored. At each clinic visit, patients will have a physical examination and a routine blood test. A Chest x-ray, CT and/or MRI scans will be done before study entry, then every 12 weeks and at the end of treatment. Disease evaluation will be carried out 12 weeks after study entry, then every 12 weeks until disease progression. After disease progression, patients will be followed up every 3 months for survival. Patients will be followed up until death or a minimum follow up period of 1 year.

Patients will be enrolled from hospitals all over the UK.

Conditions

Soft Tissue Sarcoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Axitinib

Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily.

Group Type: EXPERIMENTAL

Axitinib

Intervention Type: DRUG

Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily. A four week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.

Interventions

Axitinib

Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily. A four week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.

Intervention Type: DRUG

Other Intervention Names

AG-013736

Eligibility Criteria

Inclusion Criteria

• Pathologically confirmed soft tissue sarcoma, including:

• Angiosarcoma, including intermediate and malignant vascular tumours (WHO classification, 2002) and Kaposi's sarcoma.
• Leiomyosarcoma, including uterine, skin or non organ origin.
• Synovial sarcoma.

Exclusion Criteria

• Locally advanced or metastatic disease incurable by surgery or radiotherapy.
• Measurable disease according to RECIST criteria.
• Evidence of objective disease progression in the past 6 months, without anticancer treatment since progression.
• Patients ineligible for chemotherapy (eg. through age, clinical condition or patient refusal) or who have received no more than two prior chemotherapy regimens.
• Age >or = 16.
• WHO performance status 0, 1 or 2.
• At least 4 weeks from prior anticancer treatment (surgery, radiotherapy and systemic therapies) and full recovery from all their adverse effects.
• No evidence of preexisting uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart. The baseline systolic blood pressure readings must be < or = 140 mm Hg, and the baseline diastolic blood pressure readings must be < or = 90 mm Hg. Patients whose hypertension is controlled by antihypertensive therapies are eligible.
• Adequate physiological function:

• renal : calculated or measured creatinine clearance > or = 50 ml/min using the Cockcroft-Gault formula (see appendix 5).
• haematological: Absolute Neutrophil Count (ANC) > or = 1.5 x 109/L, platelets > or = 100 x 109/L, International Normalized Ratio (INR) < or = 1.2.
• hepatic: bilirubin within normal range, AST and ALT < or = 3 x upper limit of normal.
• cardiac: Left Ventricular Ejection Fraction (LVEF) measured by Echocardiogram or Multi Gated Acquisition Scan (MUGA) within normal range.
• Urinary protein <2+ by urine dipstick. If dipstick is >2+ then a 24-hour urine collection can be done and the patient may enter only if urinary protein is <2 g per 24 hours.
• Negative pregnancy test and agrees to comply with contraceptive measures
• Able to swallow oral medication.

• Ineligible pathological subtypes including:

• Osteosarcoma
• Ewings/Primitive Neuroectodermal Tumour (PNET sarcomas)
• Chondrosarcoma
• Gastrointestinal stromal tumours (GIST)
• Dermatofibrosarcoma protuberans (DFSP)
• Malignant mesothelioma
• Mixed mesodermal tumours of uterus
• Known central nervous system metastases.
• Age < 16.
• Current use or anticipated need for treatment with drugs that are known CYP3A4 or CYP1A2 inducers (i.e., carbamazepine, dexamethasone, felbamate, omeprazole, phenobarbital, phenytoin, primidone, rifabutin, rifampicin, and St. John"s Wort).
• Current use or anticipated need for treatment with drugs that are known potent CYP3A4 inhibitors (i.e., grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, voriconazole, erythromycin, clarithromycin, ergot derivatives, indinavir, saquinavir, ritonavir, nelfinavir and lopinavir).
• Previous malignancies (except curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix or breast) within the past 3 years.
• Heart failure > or = New York Heart Association (NYHA) class II.
• History within the previous 6 months of any blood clots in the sputum or streaky haemoptysis that was persistent (> 2 weeks) or recurrent (> 3 episodes).
• Patients with cavitating lung metastases or any metastasis abutting or invading a major pulmonary blood vessel on baseline CT or MRI scan.
• History of bleeding diathesis or coagulopathy within 12 months of study entry
• Any of the following within the 12 months prior to trial drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, deep vein thrombosis or pulmonary embolism.
• Therapeutic dose warfarin. Low molecular weight heparin is permitted.
• Regular treatment with antiplatelet medication, including aspirin >325 mg/day or NSAIDs
• History of malabsorption or major gastrointestinal tract resection likely to affect trial drug absorption.
• Pregnancy or breastfeeding. Female patients must be surgically sterile or be postmenopausal, or must agree to use two effective contraception measures during the period of therapy which should be continued for 4 weeks after the last dose of trial therapy. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy which should be continued for 4 weeks after the last dose of trial therapy . The definition of effective contraception will be based on the judgment of the Investigator or designee.

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Birmingham

OTHER

Sponsor Role: collaborator

Cancer Research UK

OTHER

Sponsor Role: collaborator

Pfizer

INDUSTRY

Sponsor Role: collaborator

Sheffield Teaching Hospitals NHS Foundation Trust

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Penella Woll, BMedSci

Role: PRINCIPAL_INVESTIGATOR

Weston Park Hospital, Sheffield, UK

Locations

Aberdeen Royal Infirmary

Aberdeen, Scotland, United Kingdom

Western General Hospital

Edinburgh, Scotland, United Kingdom

Bristol Haematology & Oncology Centre

Bristol, , United Kingdom

St. James's Hospital

Leeds, , United Kingdom

Royal Marsden Hospital

London, , United Kingdom

Royal Marsden

London, , United Kingdom

University College London Hospitals

London, , United Kingdom

Christies

Manchester, , United Kingdom

Clatterbridge Centre for Oncology

Metropolitan Borough of Wirral, , United Kingdom

Nottingham City Hospital

Nottingham, , United Kingdom

Churchill Hospital

Oxford, , United Kingdom

Penella Woll

Sheffield, , United Kingdom

Southampton General Hospital

Southampton, , United Kingdom

Countries

United Kingdom

Other Identifiers

2008-006007-23

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

STH15195

Identifier Type: -

Identifier Source: org_study_id